FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2147828078> ?p ?o ?g. }

• W2147828078 endingPage "458" @default.
• W2147828078 startingPage "453" @default.
• W2147828078 abstract "Abstract Background. The aim of this study was to assess the frequency of potentially actionable genomic alterations in breast cancer that could be targeted with approved agents or investigational drugs in clinical trials using a next-generation sequencing-based genomic profiling assay performed in a Clinical Laboratory Improvement Amendments-certified and College of American Pathologists-accredited commercial laboratory. Methods. Fifty-one breast cancers were analyzed, including primary tumor biopsies of 33 stage I–II and 18 stage IV cancers (13 soft tissue, 3 liver, and 2 bone metastases). We assessed 3,230 exons in 182 cancer-related genes and 37 introns in 14 genes often rearranged in cancer for base substitutions, indels, copy number alterations, and gene fusions. The average median sequencing depth was 1,154×. Results. We observed 158 genomic alterations in 55 genes in 48 of 51 (94%) tumors (mean 3.1, range 0–9). The average number of potentially therapeutically relevant alterations was similar in primary (1.6, range 0–4) and in heavily pretreated metastatic cancers (2.0, range 0–4) (p = .24). The most common actionable alterations were in PIK3CA (n = 9, phosphatidylinositol 3-kinase [PI3K]/mammalian target of rapamycin [mTOR] inhibitors), NF1 (n = 7, PI3K/mTOR/mitogen-activated protein kinase inhibitors), v-akt murine thymoma viral oncogene homolog 1-3 (n = 7, PI3K/mTOR/AKT inhibitors), BRCA1/2 (n = 6, poly[ADP-ribose] polymerase inhibitors), and CCND1,2 and CCNE (n = 8)/cycline dependent kinase (CDK)6 (n = 1) (CDK4/6 inhibitors), KIT (n = 1, imatinib/sunitinib), ALK (n = 1, crizotinib), FGFR1,2 (n = 5, fibroblast growth factor receptor inhibitors), and EGFR (n = 2, epidermal growth factor receptor inhibitors). Our sequencing assay also correctly identified all six cases with HER2 (ERBB2) amplification by fluorescence in situ hybridization when tumor content was adequate. In addition, two known activating HER2 mutations were identified, both in unamplified cases. Conclusion. Overall, 84% of cancers harbored at least one genomic alteration linked to potential treatment options. Systematic evaluation of the predictive value of these genomic alterations is critically important for further progress in this field." @default.
• W2147828078 created "2016-06-24" @default.
• W2147828078 creator A5001315712 @default.
• W2147828078 creator A5004434618 @default.
• W2147828078 creator A5011609796 @default.
• W2147828078 creator A5023430660 @default.
• W2147828078 creator A5033486347 @default.
• W2147828078 creator A5035120516 @default.
• W2147828078 creator A5042271475 @default.
• W2147828078 creator A5042362382 @default.
• W2147828078 creator A5061636658 @default.
• W2147828078 creator A5069309658 @default.
• W2147828078 creator A5073531557 @default.
• W2147828078 creator A5079433880 @default.
• W2147828078 creator A5083444134 @default.
• W2147828078 creator A5084877052 @default.
• W2147828078 date "2014-04-07" @default.
• W2147828078 modified "2023-10-13" @default.
• W2147828078 title "A Targeted Next-Generation Sequencing Assay Detects a High Frequency of Therapeutically Targetable Alterations in Primary and Metastatic Breast Cancers: Implications for Clinical Practice" @default.
• W2147828078 cites W1970314237 @default.
• W2147828078 cites W1974740818 @default.
• W2147828078 cites W1979946545 @default.
• W2147828078 cites W1984796696 @default.
• W2147828078 cites W2004834404 @default.
• W2147828078 cites W2019950585 @default.
• W2147828078 cites W2030845915 @default.
• W2147828078 cites W2038081635 @default.
• W2147828078 cites W2043696829 @default.
• W2147828078 cites W2063550022 @default.
• W2147828078 cites W2072513435 @default.
• W2147828078 cites W2074048861 @default.
• W2147828078 cites W2093812166 @default.
• W2147828078 cites W2095659509 @default.
• W2147828078 cites W2096283457 @default.
• W2147828078 cites W2097757428 @default.
• W2147828078 cites W2100439220 @default.
• W2147828078 cites W2102726935 @default.
• W2147828078 cites W2118167058 @default.
• W2147828078 cites W2126886805 @default.
• W2147828078 cites W2128542677 @default.
• W2147828078 cites W2132630169 @default.
• W2147828078 cites W2133105825 @default.
• W2147828078 cites W2160981405 @default.
• W2147828078 cites W2162525969 @default.
• W2147828078 cites W2166310356 @default.
• W2147828078 cites W2324850882 @default.
• W2147828078 doi "https://doi.org/10.1634/theoncologist.2013-0377" @default.
• W2147828078 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4012963" @default.
• W2147828078 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24710307" @default.
• W2147828078 hasPublicationYear "2014" @default.
• W2147828078 type Work @default.
• W2147828078 sameAs 2147828078 @default.
• W2147828078 citedByCount "53" @default.
• W2147828078 countsByYear W21478280782014 @default.
• W2147828078 countsByYear W21478280782015 @default.
• W2147828078 countsByYear W21478280782016 @default.
• W2147828078 countsByYear W21478280782017 @default.
• W2147828078 countsByYear W21478280782018 @default.
• W2147828078 countsByYear W21478280782019 @default.
• W2147828078 countsByYear W21478280782020 @default.
• W2147828078 countsByYear W21478280782021 @default.
• W2147828078 countsByYear W21478280782022 @default.
• W2147828078 countsByYear W21478280782023 @default.
• W2147828078 crossrefType "journal-article" @default.
• W2147828078 hasAuthorship W2147828078A5001315712 @default.
• W2147828078 hasAuthorship W2147828078A5004434618 @default.
• W2147828078 hasAuthorship W2147828078A5011609796 @default.
• W2147828078 hasAuthorship W2147828078A5023430660 @default.
• W2147828078 hasAuthorship W2147828078A5033486347 @default.
• W2147828078 hasAuthorship W2147828078A5035120516 @default.
• W2147828078 hasAuthorship W2147828078A5042271475 @default.
• W2147828078 hasAuthorship W2147828078A5042362382 @default.
• W2147828078 hasAuthorship W2147828078A5061636658 @default.
• W2147828078 hasAuthorship W2147828078A5069309658 @default.
• W2147828078 hasAuthorship W2147828078A5073531557 @default.
• W2147828078 hasAuthorship W2147828078A5079433880 @default.
• W2147828078 hasAuthorship W2147828078A5083444134 @default.
• W2147828078 hasAuthorship W2147828078A5084877052 @default.
• W2147828078 hasBestOaLocation W21478280781 @default.
• W2147828078 hasConcept C121608353 @default.
• W2147828078 hasConcept C126322002 @default.
• W2147828078 hasConcept C16930146 @default.
• W2147828078 hasConcept C184235292 @default.
• W2147828078 hasConcept C190283241 @default.
• W2147828078 hasConcept C2775922572 @default.
• W2147828078 hasConcept C2775930923 @default.
• W2147828078 hasConcept C2776087337 @default.
• W2147828078 hasConcept C2778472372 @default.
• W2147828078 hasConcept C2779490328 @default.
• W2147828078 hasConcept C2779744173 @default.
• W2147828078 hasConcept C2781187634 @default.
• W2147828078 hasConcept C37307934 @default.
• W2147828078 hasConcept C502942594 @default.
• W2147828078 hasConcept C526805850 @default.
• W2147828078 hasConcept C530470458 @default.
• W2147828078 hasConcept C54355233 @default.
• W2147828078 hasConcept C57074206 @default.
• W2147828078 hasConcept C71924100 @default.

• next